Cargando…
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
BACKGROUND: Previous studies have reported that epidermal growth factor receptor (EGFR) mutation in tumor tissue and peripheral blood can predict the response to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). However, the heterogeneity of the sample sources makes it diff...
Autores principales: | Xu, Fei, Wu, Jingxun, Xue, Cong, Zhao, Yuanyuan, Jiang, Wei, Lin, Liping, Wu, Xuan, Lu, Yachao, Bai, Hua, Xu, Jiasen, Zhu, Guanshan, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525047/ https://www.ncbi.nlm.nih.gov/pubmed/23251095 http://dx.doi.org/10.2147/OTT.S37289 |
Ejemplares similares
-
Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
por: Yunxia, Zuo, et al.
Publicado: (2010) -
Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
por: Yunxia, Zuo, et al.
Publicado: (2010) -
Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
por: Xu, Chong‐Rui, et al.
Publicado: (2016) -
A Modified Extraction Method of Circulating Free DNA for Epidermal Growth Factor Receptor Mutation Analysis
por: Yuan, Haihua, et al.
Publicado: (2012) -
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)